Cancer Biopsy Market Size To Hold USD 66.1 Billion By 2023

Published Date : 23 Jan 2023

The global cancer biopsy market size was reached USD 28.36 billion in 2022 and is expected to hold around USD 66.1 billion by 2030, growing at a CAGR of 17.6% from 2022 to 2030.

A biopsy is a procedure that determines if you have cancer or some other disease. In this, a sample of cells from your body or a piece of tissue is removed to be tested in a laboratory. You must undergo a biopsy if you're experiencing certain signs and symptoms. C.T. scans or MRIs are beneficial but can't determine the difference between cancerous and non-cancerous cells. 

The cells are collected for closer examination. There are various types of biopsy, such as needle biopsy, endoscopic biopsy, skin biopsy, bone marrow biopsy, and surgical biopsy. A needle biopsy is inserted into the skin to collect cells from a suspicious area. It is a percutaneous tissue biopsy. It is used in suspicious areas. The doctors can feel these suspicious areas through your skin, such as breast lumps. 

Needle biopsy combines an imaging procedure to collect cells from a particular area that can't be felt via the skin. It further includes Fine-needle aspiration, Core needle biopsy, Vacuum-assisted biopsy, and Image-guided biopsy. An endoscope is used with a light to see parts inside the body in an endoscopic biopsy. A small tissue sample is taken by the special tools passed through the tube. It can be inserted via the mouth, urinary tract, rectum, or a small incision in your skin.

In a skin biopsy, cells from the surface of your body are removed. It is used to diagnose skin conditions, including melanoma and other cancers. It includes Shave biopsy, Punch biopsy, Incisional biopsy, and Excisional biopsy. In bone marrow biopsy, a sample of bone marrow is drawn out of the back of your hipbone using a long needle. This procedure is recommended if the doctor suspects cancer is affecting your bone marrow. 

It is used to diagnose various blood problems, both cancerous and not cancerous. It can diagnose blood cancers like leukemia, lymphoma, and multiple myeloma. In a surgical biopsy, an incision is made in your skin to access the questionable area of cells. This procedure is recommended if the suspected cells can't be accessed with other biopsy procedures. Example: surgery to remove a breast lump or a lymph node.  

Growth Factors 

The rising prevalence of oncology indications majorly drives the global cancer biopsy market. The growing geriatric population and the advent of liquid biopsy fuel market growth. The developments in biopsy techniques propel the growth of the market. Various techniques are used in the oncology diagnostics field, such as endoscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsy is highly preferred. 

The benefits offered by fine-needle aspiration (FNA) type needle biopsies accelerate the market growth. It takes lesser time for the outcomes and is less invasive. Rapid advancements in image-guided biopsies catalyze market growth. The expanding applications of image-guided biopsies supplement the market growth. The multi-parametric magnetic resonance (M.R.) imaging-based biopsies have been gaining immense popularity since their inception. 

It lowers false-negative results and confirms tumor presence by identifying genetic markers in the blood. It offers various benefits such as lesser complexity, less time consumption, less pain during the biopsy, and cost-effectiveness. Several companies working in diagnostics are entering this market. The increasing use of liquid biopsy for cancer diagnosis, screening, prognosis, and treatment monitoring propel the market growth. 

The market players are undertaking strategic initiatives, which are expected to fuel the growth of the market. The liquid biopsy is used in people who cannot undergo a tissue biopsy. It provides real-time information about a tumor and is minimally invasive and cost-effective.  

Cancer Biopsy Market Report Scope

Report Coverage Details
Market Size in 2022 USD 28.36 Billion
Market Size by 2030 USD 66.1 Billion
Growth Rate from 2022 to 2030 CAGR of 17.6%
Base Year 2022
Forecast Period 2022 to 2030
Segments Covered By Type, By Product and By Application
Regions Covered  North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Report Highlights: 

  • Based on the type, tissue biopsy dominates the market as it is the most widely used procedure and is extensively used across a variety of cancer diagnosis applications. This biopsy is safe and efficient, and also cost-effective. The liquid biopsy is expected to grow at a fast rate due to the increasing preference for liquid biopsy. It provides disease assessments from both the primary and distant tumor locations. It is used in personalized medical treatment. 
  • Based on the product, kits and consumables dominate the market due to the availability of the popular and heavy investments made by key market players in the industry. The instruments are expected to grow at a rapid rate due to the increasing demand for quick tools and kits. 
  • Based on the application, breast cancer dominated the market due to the increasing cases of breast cancer. Prostate cancer is expected to grow at a faster rate due to the rising cases of prostate cancer.

Regional Snapshots

Based on the region, North America dominated the market. It accounted for the largest revenue share due to the widespread availability of unique kits well-suited for quick diagnostic applications. The availability of technologically advanced instruments and developed healthcare systems boost the overall market growth across the region. 

On the other hand, Asia Pacific is expected to grow at a fast rate due to the increasing cases of lung cancer, rising awareness among the patients, increased cancer patients, upgraded infrastructure, escalating demand for noninvasive illness detection, and new product launches. 

Market Dynamics: 

Driver: Increasing prevalence of cancer 

The increasing prevalence of cancer significantly contributes to market growth. The growing demand for noninvasive treatment positively influences the market growth. The rising use of liquid biopsy for personalized medicine catalyzes market growth. The availability of technologically advanced instruments creates a positive outlook for the market. 

The inflating disposable incomes of the individuals and the high healthcare expenditure propel the market growth. The upgraded infrastructure and the rapid adoption of advanced methods favor market growth. The surging demand for noninvasive illness detection boosts the overall market growth. The rising need for safe medications fuels market growth.  

Opportunity: High demand for biopsy 

Every year many people are diagnosed with different kinds of cancer. The reason behind the surge in cancer is changes in lifestyle, tobacco consumption, smoking, unhealthy eating habits, hepatitis B and C infection, etc. Biopsy offers various benefits such as monitoring, early prognosis, cost-efficiency, patient comfort, etc. The high demand for biopsy for cancer diagnosis offers lucrative opportunities for market growth.  

Restraint: High costs 

The cost of cancer biopsy is very high, especially for people belonging to the low-income or middle-class group. The cost of molecular testing is very high. Furthermore, the lack of professionals to interpret the results restricts market growth. The treatment programs are very complicated. Liquid biopsy is also expensive. All these factors restrict the cancer biopsy market growth. 

Challenge: Failure in the detection of cancer 

There are rare chances of getting failed in detecting the lesions. In the case of a less invasive breast biopsy, one can also fail to determine the illness's extent. These limitations are challenging the growth of the cancer biopsy market. 

Key Developments: 

  • In March 2021, the NextSeq 550Dx platform and accompanying reagent kits of Illumina Inc. received medical device registration in Russia.  
  • In January 2017, Guardant Health Inc. entered into an agreement with MD Anderson to make complete liquid biopsy a standard of care in cancer. 

Major Key Players

  • Myriad Genetics Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Bio-Rad Laboratories Inc.
  • Agena Bioscience Inc.
  • Personal Genome Diagnostics Inc.
  • Exosome Diagnostics Inc.
  • ANGLE Plc.
  • F. Hoffmann-La Roche Ltd.

Market Segmentation

By Product

  • Instruments
  • Kits and Consumables
  • Services

By Type

  • Tissue Biopsies
    • Fine Needle Aspiration (FNA)
    • Core Needle Biopsy (CNB)
    • Needle Biopsies
    • Surgical Biopsies
  • Liquid Biopsies
  • Others

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at| +1 9197 992 333